2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The diagnosis of pulmonary tuberculosis (TB) in patients suspected of lung cancer is difficult because of the similarities in signs, symptoms, and radiologic results. The clinical and radiologic characteristics of the co-occurrence of pulmonary TB and lung cancer have not been fully evaluated.

          Methods

          Patients diagnosed with lung cancer and active pulmonary TB from January 2009 to December 2017 in four hospitals of the Catholic University of Korea were retrospectively reviewed. The clinical characteristics, including the TB diagnosis methods, lung cancer pathology, staging, initial radiographic features, and survival were analyzed and compared to 575 lung cancer patients without active pulmonary TB from the same hospitals.

          Results

          Forty-eight (0.48%) of the 9,936 lung cancer patients had active pulmonary TB confirmed for M. tuberculosis at the time of the initial cancer diagnosis. The majority of the patients (95.9%) had non-small cell lung cancer and the most frequent findings were a mass-like lesion (79.2%) and separate nodules (75%). When compared to lung cancer patients without TB, the body mass index (BMI) was lower (21.4 vs. 23.1, P=0.001) and clinical stages were advanced in the lung cancer patients with TB; T3-4 (70.9% vs. 50.6%, P=0.002), N2-3 (85.2% vs. 55.6%, P<0.001); M1 (65.9% vs. 44.5%, P=0.007). Interestingly, lung cancer with TB was associated with lower mortality [hazard ratio (HR) =0.35, 95% CI: 0.21–0.60].

          Conclusions

          Rarely diagnosed concurrent active TB in lung cancer patients was associated with lower BMI and advanced clinical stages. Active investigation of and treatment for active pulmonary TB in lung cancer patients might possibly improve patient outcomes.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

          Background Tumor-associated macrophages (TAMs) play an important role in growth, progression and metastasis of tumors. In non-small cell lung cancer (NSCLC), TAMs' anti-tumor or pro-tumor role is not determined. Macrophages are polarized into M1 (with anti-tumor function) and M2 (with pro-tumor function) forms. This study was conducted to determine whether the M1 and M2 macrophage densities in NSCLC are associated with patient's survival time. Methods Fifty patients with an average of 1-year survival (short survival group) and 50 patients with an average of 5-year survival (long survival group) were included in this retrospective study. Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical double-staining of CD68/HLA-DR (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded fashion. The M1 and M2 macrophage densities in the tumor islets, stroma, or islets and stroma were determined using computer-aided microscopy. Correlation of the macrophage densities and patient's survival time was analyzed using the Statistical Package for the Social Sciences. Results Approximately 70% of TAMs were M2 macrophages and the remaining 30% were M1 macrophages in NSCLC. The M2 macrophage densities (approximately 78 to 113 per mm2) in the tumor islets, stroma, or islets and stroma were not significantly different between the long survival and short survival groups. The M1 macrophage densities in the tumor islets (approximately 70/mm2) and stroma (approximately 34/mm2) of the long survival group were significantly higher than the M1 macrophage densities in the tumor islets (approximately 7/mm2) and stroma (13/mm2) of the short survival group (P < 0.001 and P < 0.05, respectively). The M2 macrophage densities were not associated with patient's survival time. The M1 macrophage densities in the tumor islets, stroma, or islets and stroma were positively associated with patient's survival time in a univariate analysis (P < 0.01 or 0.001). In a multivariate Cox proportional hazards analysis, the M1 macrophage density in the tumor islets was an independent predictor of patient's survival time. Conclusions The M1 macrophage density in the tumor islets is an independent predictor of survival time in NSCLC patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study.

            Given one third of the human population have been infected with tuberculosis, it is important to delineate the relationship between tuberculosis and lung cancer. This study explored whether contracting pulmonary tuberculosis is associated with an increased risk of developing lung cancers. In a cohort of 716,872 insured subjects, free from cancers, aged 20 years and older, 4480 patients with newly diagnosed tuberculosis were identified from the universal insurance claims in 1998-2000 and tracked until 2007 with the remaining insured without tuberculosis. We compared the incidence of lung cancers between the two cohorts and measured the associated hazard of developing lung cancer. The incidence of lung cancers was approximately 11-fold higher in the cohort of patients with tuberculosis than nontuberculosis subjects (26.3 versus 2.41 per 10,000 person-years). Cox proportional hazard regression analysis showed a hazard ratio of 4.37 (95% confidence interval [CI]: 3.56-5.36) for the tuberculosis cohort after adjustment for the sociodemographic variables or 3.32 (95% CI: 2.70-4.09) after further adjustment for chronic obstructive pulmonary disease (COPD), smoking-related cancers (other than lung cancer), etc. The hazard ratio increased to 6.22 (95% CI: 4.87-7.94) with the combined effect with COPD or to 15.5 (95% CI: 2.17-110) with the combined effect with other smoking-related cancers. This study provides a compelling evidence of increased lung cancer risk among individuals with tuberculosis. The risk may increase further with coexisting COPD or other smoking-related cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study.

              The possible effect of pulmonary tuberculosis (TB) on subsequent lung cancer development has been suspected, but the evidence remains inconsistent. The purpose of this study was to perform a nationwide population-based cohort study to investigate the risk of lung cancer after pulmonary TB infection.
                Bookmark

                Author and article information

                Journal
                Transl Cancer Res
                Transl Cancer Res
                TCR
                Translational Cancer Research
                AME Publishing Company
                2218-676X
                2219-6803
                August 2022
                August 2022
                : 11
                : 8
                : 2671-2680
                Affiliations
                [1 ]deptDivision of Allergy, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine , The Catholic University of Korea , Seoul, Republic of Korea;
                [2 ]deptDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal medicine, Bucheon St Mary’s Hospital, College of Medicine , The Catholic University of Korea , Seoul, Republic of Korea;
                [3 ]deptDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, Cancer Research Institute, College of Medicine , The Catholic University of Korea , Seoul, Republic of Korea;
                [4 ]deptDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St Mary’s Hospital , The Catholic University of Korea , Seoul, Republic of Korea;
                [5 ]deptDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Eunpyeong St Mary’s Hospital, College of Medicine , The Catholic University of Korea , Seoul, Republic of Korea;
                [6 ]deptCancer Research Institute, College of Medicine , The Catholic University of Korea , Seoul, Republic of Korea;
                [7 ]deptPulmonology Lab., Postech-Catholic Biomedical Engineering Institute, College of Medicine , The Catholic University of Korea , Seoul, Korea
                Author notes

                Contributions: (I) Conception and design: HY Lee, CD Yeo; (II) Administrative support: HY Lee, SH Lee, CD Yeo; (III) Provision of study materials or patients: JW Heo, HS Kang, JY Kang, JW Kim, SH Lee, SJ Kim; (IV) Collection and assembly of data: JW Heo, HS Kang, JY Kang, JW Kim, SH Lee, SJ Kim; (V) Data analysis and interpretation: HY Lee, SH Lee, CD Yeo; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                Correspondence to: Chang Dong Yeo, MD, PhD. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea. Email: brainyeo@ 123456catholic.ac.kr .
                Article
                tcr-11-08-2671
                10.21037/tcr-22-272
                9459664
                36093537
                b21ae9e3-4e57-4bb9-a266-c5c6f8bc5e4d
                2022 Translational Cancer Research. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 08 February 2022
                : 07 June 2022
                Funding
                Funded by: the National Research Foundation of Korea (NRF) grant funded by the Korean government
                Award ID: No. NRF- 2020R1F1A1066281
                Categories
                Original Article

                lung cancer,mycobacterium tuberculosis,neoplasm staging

                Comments

                Comment on this article